Zobrazeno 1 - 10
of 46
pro vyhledávání: '"MARK LAKSHMANAN"'
Autor:
Hertzel C. Gerstein, Chinthanie Ramasundarahettige, Alvero Avezum, Jan Basile, Ignacio Conget, William C. Cushman, Gilles R. Dagenais, Edward Franek, Mark Lakshmanan, Fernando Lanas, Lawrence A. Leiter, Nana Pogosova, Jeffrey Probstfield, Peter J. Raubenheimer, Matthew Riddle, Jonathan Shaw, Wayne H.-H. Sheu, Theodora Temelkova-Kurktschiev, Ibrahim Turfanda, Denis Xavier
Publikováno v:
Cardiovascular Diabetology, Vol 21, Iss 1, Pp 1-8 (2022)
Abstract Background The estimated glomerular filtration rate (eGFR) and the albumin-to-creatinine ratio (ACR) are risk factors for diabetes-related outcomes. A composite that captures information from both may provide a simpler way of assessing risk.
Externí odkaz:
https://doaj.org/article/d7e83d72a5384fcfbe6664e1096dbb38
Autor:
Kelley R.H. Branch, Gilles R. Dagenais, Alvaro Avezum, Jan Basile, Ignacio Conget, William C. Cushman, Petr Jansky, Mark Lakshmanan, Fernando Lanas, Lawrence A. Leiter, Prem Pais, Nana Pogosova, Peter J. Raubenheimer, Lars Ryden, Jonathan E. Shaw, Wayne H.H. Sheu, Theodora Temelkova‐Kurktschiev, M. Angelyn Bethel, Hertzel C. Gerstein, Ramasundarahettige Chinthanie, Jeffrey L. Probstfield
Publikováno v:
European Journal of Heart Failure. 24:1805-1812
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2ac626ffc6207dd342aff9abcbbb627b
https://doi.org/10.1002/ejhf.2670
https://doi.org/10.1002/ejhf.2670
Autor:
Hertzel C. Gerstein, Shun-Fu Lee, Guillaume Paré, M. Angelyn Bethel, Helen M. Colhoun, Anastasia Hoover, Mark Lakshmanan, Yanzhu Lin, Valentino Pirro, Hui-Rong Qian, Giacomo Ruotolo, Lars Ryden, Jonathan M. Wilson, Kevin L. Duffin
OBJECTIVE The glucagon-like peptide-1 receptor agonist dulaglutide reduced MACE in the Researching Cardiovascular Events with a Weekly Incretin in Diabetes (REWIND) trial. This article expores the relationship of selected biomarkers to both dulagluti
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2640ca757c8cf50993017da4bd7b9737
https://doi.org/10.2337/figshare.22120097
https://doi.org/10.2337/figshare.22120097
Autor:
JONATHAN M. WILSON, GUILLAUME PARE, SHUN FU LEE, HELEN M. COLHOUN, HUI-RONG QIAN, VALENTINA PIRRO, ANASTASIA HOOVER, MARK LAKSHMANAN, GIACOMO RUOTOLO, KEVIN L. DUFFIN, HERTZEL C. GERSTEIN
Publikováno v:
Diabetes. 71
In the REWIND trial, dulaglutide (DU) reduced the risk of CV outcomes compared with placebo (PL) (Major Adverse Cardiovascular Event [MACE]-3 hazard ratio 0.88) . This post hoc analysis studied circulating protein biomarkers associated with CV events
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::406a813d146475b65a3c3fbd37a0f23f
https://doi.org/10.2337/db22-725-p
https://doi.org/10.2337/db22-725-p
Autor:
Hertzel C. Gerstein, Edward Franek, Oralee J. Varnado, Manige Konig, Lawrence A. Leiter, Sohini Raha, Denis Xavier, William C. Cushman, Matthew C. Riddle, Charles Atisso, Peter J Raubenheimer, Mark Lakshmanan
Publikováno v:
The Journal of Clinical Endocrinology and Metabolism
Context Dulaglutide reduced major adverse cardiovascular events (MACE) in the Researching Cardiovascular Events with a Weekly INcretin in Diabetes (REWIND) trial. Its efficacy and safety in older vs younger patients have not been explicitly analyzed.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::16434e15c275b175f429b93b8829fca6
https://doi.org/10.1210/clinem/dgab065
https://doi.org/10.1210/clinem/dgab065
Autor:
Fady T. Botros, Anita Y.M. Kwan, Katherine R. Tuttle, Manige Konig, Brian Rayner, Linda Shurzinske, Mark Lakshmanan
Publikováno v:
Kidney360
Background In the AWARD-7 trial of participants with type 2 diabetes (T2DM) and moderate-to-severe CKD, dulaglutide (DU) treatment slowed decline in eGFR compared with insulin glargine (IG). Treatment with doses of either DU or IG resulted in similar
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0580d38eb54c0eb3fac2c1236a87eab3
https://doi.org/10.34067/kid.0005852020
https://doi.org/10.34067/kid.0005852020
Autor:
Wayne Huey-Herng Sheu, Hertzel C. Gerstein, Alvaro Avezum, Peter J Raubenheimer, Giulia Ferrannini, William C. Cushman, Jonathan E. Shaw, Nana Pogosova, Jeffrey L. Probstfield, Matyas Keltai, Mark Lakshmanan, Helen M. Colhoun, Linda Mellbin, Leanne Dyal, Petr Jansky, Rafael Diaz, Lawrence A. Leiter, Lars Rydén, Fernando Lanas, Jan Basile, Matthew C. Riddle, Valdis Pīrāgs, Gilles R. Dagenais, Patricio Lopez-Jaramillo, Prem Pais
Publikováno v:
European Heart Journal. 42:2565-2573
Digital
Objective Recent European Guidelines for Diabetes, Prediabetes and Cardiovascular Diseases introduced a shift in managing patients with type 2 diabetes at high risk for or established cardiovascular (CV) disease by recommending GLP-1 rec
Objective Recent European Guidelines for Diabetes, Prediabetes and Cardiovascular Diseases introduced a shift in managing patients with type 2 diabetes at high risk for or established cardiovascular (CV) disease by recommending GLP-1 rec
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::382ae118a3ac5cc35bb6a84df9d3f285
https://doi.org/10.1093/eurheartj/ehaa777
https://doi.org/10.1093/eurheartj/ehaa777
Autor:
Matthew C. Riddle, Theodora Temelkova-Kurktschiev, Markolf Hanefeld, Wayne H-H Sheu, Ernesto Germán Cardona Muñoz, Hertzel C. Gerstein, Alvaro Avezum, William C. Cushman, Robert G. Hart, Rafael Diaz, Jan Basile, Nicolae Hancu, Helen M. Colhoun, Fady T. Botros, Fernando Lanas, Lars Rydén, Stephanie Hall, Patricio Lopez-Jaramillo, Lawrence A. Leiter, Petr Jansky, Jonathan E. Shaw, Matyas Keltai, Ignacio Conget, Mark Lakshmanan, Charles Atisso, Jeffrey L. Probstfield, Nana Pogosova, Peter J Raubenheimer, Leanne Dyal
Publikováno v:
The Lancet Diabetes & Endocrinology. 8:106-114
Summary Background Cardiovascular outcome trials have suggested that glucagon-like peptide 1 (GLP-1) receptor agonists might reduce strokes. We analysed the effect of dulaglutide on stroke within the researching cardiovascular events with a weekly in
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::650198a64065c9515c8db9905df031e1
https://doi.org/10.1016/s2213-8587(19)30423-1
https://doi.org/10.1016/s2213-8587(19)30423-1
Autor:
Hertzel C. Gerstein, Manige Konig, Charles Atisso, Kelley R. Branch, Matthew C. Riddle, Helen M. Colhoun, Reema Mody, Mark Lakshmanan, Sohini Raha
Publikováno v:
Cardiovascular Diabetology
Cardiovascular Diabetology, Vol 20, Iss 1, Pp 1-7 (2021)
Cardiovascular Diabetology, Vol 20, Iss 1, Pp 1-7 (2021)
Background The REWIND trial demonstrated cardiovascular (CV) benefits to patients with type 2 diabetes and multiple CV risk factors or established CV disease. This exploratory analysis evaluated the degree to which the effect of dulaglutide on CV ris
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::05134defac113e8906fe1ccce09b4b40
https://doi.org/10.1186/s12933-021-01386-4
https://doi.org/10.1186/s12933-021-01386-4
Autor:
Fady T. Botros, Alan G. Zimmermann, Katherine R. Tuttle, D. Bradley Woodward, Brian Rayner, Mark Lakshmanan
Publikováno v:
Diabetes, Obesity and Metabolism. 21:1493-1497
In patients with type 2 dibetes and moderate-to-severe chronic kidney disease, dulaglutide treatment led to body weight (BW) loss and lesser eGFR decline compared to insulin glargine. As BW may affect muscle mass, creatinine-based eGFR can be altered
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::65f2fcddcdb185a5a8ec97a807350263
https://doi.org/10.1111/dom.13668
https://doi.org/10.1111/dom.13668